XUP Stock Overview
A late-stage biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 5/6 |
| Past Performance | 3/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Genfit S.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €4.00 |
| 52 Week High | €5.67 |
| 52 Week Low | €2.93 |
| Beta | 1.12 |
| 11 Month Change | -20.10% |
| 3 Month Change | 3.36% |
| 1 Year Change | 35.19% |
| 33 Year Change | 33.52% |
| 5 Year Change | -71.61% |
| Change since IPO | -80.98% |
Recent News & Updates
Recent updates
Shareholder Returns
| XUP | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -5.1% | -0.7% | 0.2% |
| 1Y | 35.2% | -17.2% | 8.5% |
Return vs Industry: XUP exceeded the German Biotechs industry which returned -17.2% over the past year.
Return vs Market: XUP exceeded the German Market which returned 8.5% over the past year.
Price Volatility
| XUP volatility | |
|---|---|
| XUP Average Weekly Movement | 8.5% |
| Biotechs Industry Average Movement | 6.5% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.9% |
| 10% least volatile stocks in DE Market | 2.3% |
Stable Share Price: XUP's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: XUP's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1999 | 169 | M. Prigent | www.genfit.com |
Genfit S.A., a late-stage biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; VS-01 for the treatment of Urea Cycle Disorder (UCD) and Organic Acidemia Disorder (OAD); GNS561, which is in Phase 1b/2a trial to treat patients with cholangiocarcinoma (CCA); VS-01-ACLF and Nitazoxanide (NTZ), which is in Phase 1 trial to treat acute-on-chronic liver failure, as well as VS-02-HE, which is in preclinical trial for the treatment of Reduction of Hyperammonemia and the Stabilization of Blood Ammonia; CML-022; SRT-015, an ASK1 inhibitor targets the inhibition of cellular apoptosis, inflammation, and fibrosis.
Genfit S.A. Fundamentals Summary
| XUP fundamental statistics | |
|---|---|
| Market cap | €202.44m |
| Earnings (TTM) | €22.27m |
| Revenue (TTM) | €80.47m |
9.1x
P/E Ratio2.5x
P/S RatioIs XUP overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| XUP income statement (TTM) | |
|---|---|
| Revenue | €80.47m |
| Cost of Revenue | €0 |
| Gross Profit | €80.47m |
| Other Expenses | €58.20m |
| Earnings | €22.27m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.45 |
| Gross Margin | 100.00% |
| Net Profit Margin | 27.67% |
| Debt/Equity Ratio | 63.9% |
How did XUP perform over the long term?
See historical performance and comparison